🇺🇸 Cisplatin and Docetaxel in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 7
Most-reported reactions
- Asthenia — 1 report (14.29%)
- Dizziness — 1 report (14.29%)
- Dysstasia — 1 report (14.29%)
- Fall — 1 report (14.29%)
- Loss Of Consciousness — 1 report (14.29%)
- Orthostatic Hypotension — 1 report (14.29%)
- Syncope — 1 report (14.29%)
Other Oncology approved in United States
Frequently asked questions
Is Cisplatin and Docetaxel approved in United States?
Cisplatin and Docetaxel does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Cisplatin and Docetaxel in United States?
Swiss Cancer Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.